Cost of sales for Q1 2024 was $10,700,000 including $2,400,000 for the amortization of intangible assets related to our neratinib license. Cost of sales for Q4 2023 was $24,300,000 dollars Going forward, we will continue to recognize amortization of milestones to the licensor of about $2,400,000 per quarter as cost of sales. For fiscal year 2024, Puma anticipates that net NERLYNX product revenue will be in the range of $183,000,000 to $190,000,000 We also anticipate that our gross to net adjustment for the full year 2024 will be between 21.5 percent 22.5 percent, higher than 2023 due to the impact of inflation reduction act and higher expected Medicaid revenues. In addition, for the fiscal year 2024, we anticipate receiving royalties from our partners around the world in the range of $30,000,000 to $33,000,000 We expect licenses license revenue in 2024 in the range of $1,000,000 to 2,000,000 dollars We also expect that net income for the full year will be in the range of $12,000,000 to 15,000,000 dollars We anticipate that for Q2 2024, NERLYNX net product revenue will be in the range of $43,000,000 to 45,000,000 dollars Also, we expect Q2 royalty revenues will be in the range of $2,500,000 to $3,000,000 and we anticipate no license revenue.